AF
CRSP icon

Avanza Fonder’s CRISPR Therapeutics CRSP Stock Holding History

Avanza Fonder’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-25,341
Closed -$866K – 448
2025
Q1 		$866K Buy
+25,341
New +$1.07M 0.03% 361

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Avanza Fonder's CRSP Position: Q2 2025 in Review

Avanza Fonder sold out of CRISPR Therapeutics (CRSP) in Q2 2025, closing a stake of 25,341 shares — an estimated $866K sold.

Avanza Fonder first reported a position in CRSP in Q1 2025 and held it in 1 quarter. The position peaked at $866K in Q1 2025. 433 funds tracked by Wall St. Rank hold CRSP as of Q2 2025.

  • Avanza Fonder reported no remaining CRISPR Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Avanza Fonder sold 25,341 CRISPR Therapeutics shares in Q2 2025, an estimated $866K.
  • Avanza Fonder first reported a position in CRISPR Therapeutics in Q1 2025 and held it in 1 quarter.
  • Avanza Fonder's CRISPR Therapeutics position peaked at $866K in Q1 2025.
  • 433 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2025.

Based on Avanza Fonder's 13F filing for Q2 2025, filed 14 Jul 2025.